Biology subjects

Williams, D. A.

Publications and source records attributed to Williams, D. A..

3 recordsLinked to original sources

bioRxiv2024

Advancing cooperative breeding research with a peer-reviewed and "live" Cooperative-Breeding Database (Co-BreeD)

Research on cooperative breeding (a system with the core characteristic of individuals providing care for the offspring of others) is important for understanding sociality and cooperation. However, large-scale comparative analyses on the drivers and consequences of cooperation frequently use considerably inaccurate datasets (e.g. due to inconsistent definitions and outdated information). To advance comparative research on cooperative breeding, we introduce the Cooperative-Breeding Database (Co-BreeD), a growing database of key socio-biological parameters of birds and mammals. First, we describe Co-BreeDs structure as a (i) sample-based (i.e. multiple samples per species linked to an exact sampling location and period), (ii) peer-reviewed and (iii) updatable resource. Respectively, these curating principles allow for (i) investigating intra- and inter-species variation and linking between fine-scale social and environmental parameters, (ii) accuracy and (iii) continuous correction and expansion with the publication of new data. Second, we present the first Co-BreeD dataset, which estimates the prevalence of breeding events with potential alloparents in 265 samples from 233 populations of 150 species, including 2 human societies (N = 26,366 breeding events). We conclude by demonstrating (i) how Co-BreeD facilitates more accurate comparative research (e.g. increased explanatory power by enabling the study of cooperative breeding as a continuous trait, and statistically accounting for the sampling error probabilities), and (ii) that cooperative breeding in birds and mammals is more prevalent than currently estimated.

animal behavior and cognition↗

bioRxiv2023

Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells

Gene editing the BCL11A erythroid enhancer is a validated approach to fetal hemoglobin (HbF) induction for {beta}-hemoglobinopathy therapy, though heterogeneity in edit allele distribution and HbF response may impact its safety and efficacy. Here we compared combined CRISPR-Cas9 endonuclease editing of the BCL11A +58 and +55 enhancers with leading gene modification approaches under clinical investigation. We found that combined targeting of the BCL11A +58 and +55 enhancers with 3xNLS-SpCas9 and two sgRNAs resulted in superior HbF induction, including in engrafting erythroid cells from sickle cell disease (SCD) patient xenografts, attributable to simultaneous disruption of core half E-box/GATA motifs at both enhancers. We corroborated prior observations that double strand breaks (DSBs) could produce unintended on- target outcomes in hematopoietic stem and progenitor cells (HSPCs) such as long deletions and centromere-distal chromosome fragment loss. We show these unintended outcomes are a byproduct of cellular proliferation stimulated by ex vivo culture. Editing HSPCs without cytokine culture bypassed long deletion and micronuclei formation while preserving efficient on-target editing and engraftment function. These results indicate that nuclease editing of quiescent hematopoietic stem cells (HSCs) limits DSB genotoxicity while maintaining therapeutic potency and encourages efforts for in vivo delivery of nucleases to HSCs.

genetics↗

bioRxiv2022

Validation of a small molecule inhibitor of PDE6D-RAS interaction with potent anti-leukemic effects

RAS mutations prevalent in high-risk leukemia have been linked to relapse and chemotherapy resistance. Efforts to directly target RAS proteins have been largely unsuccessful. However, since RAS-mediated transformation is dependent on signaling through the RAS-related C3 botulinum toxin substrate (RAC) small GTPase, we hypothesized that targeting RAC may be an effective therapeutic approach in RAS mutated tumors. Here we describe multiple small molecules capable of inhibiting RAC activation in acute lymphoblastic leukemia cell lines. One of these, DW0254, also demonstrates promising anti-leukemic activity in RAS-mutated cells. Using chemical proteomics and biophysical methods, we identified the hydrophobic pocket of phosphodiester 6 subunit delta (PDE6D), a known RAS chaperone, as a target for this compound. Inhibition of RAS localization to the plasma membrane upon DW0254 treatment is associated with RAC inhibition through a phosphatidylinositol-3-kinase/AKT-dependent mechanism. Our findings provide new insights on the importance of PDE6D-mediated transport for RAS-dependent RAC activation and leukemic cell survival.

cancer biology↗